Asset formula

Carnegie Capital Asset Management LLC increases its stake in The Clorox Company (NYSE:CLX)


Carnegie Capital Asset Management LLC increased its holdings in The Clorox Company (NYSE:CLX – Get Rating) by 13.6% in the first quarter, according to the company in its latest 13F filing with the Securities and Exchange Commission. The fund held 7,997 shares of the company after acquiring an additional 957 shares during the period. Carnegie Capital Asset Management LLC’s holdings in Clorox were worth $1,112,000 at the end of the last quarter.

Other major investors have also changed their positions in the company. Dark Forest Capital Management LP bought a new position in Clorox stock in Q3 valued at around $25,000. Newbridge Financial Services Group Inc. increased its stake in Clorox by 185.2% in the fourth quarter. Newbridge Financial Services Group Inc. now owns 154 shares of the company worth $27,000 after purchasing an additional 100 shares in the last quarter. TAP Consulting LLC purchased a new stake in Clorox in the fourth quarter worth approximately $27,000. FSB Premier Wealth Management Inc. acquired a new stake in Clorox in the fourth quarter worth approximately $28,000. Finally, Financial Avengers Inc. increased its stake in Clorox by 119.7% in the fourth quarter. Financial Avengers Inc. now owns 167 shares of the company worth $29,000 after buying 91 additional shares in the last quarter. 77.28% of the shares are held by hedge funds and other institutional investors.

In other news, Director A D. David Mackay sold 1,000 shares of the company in a trade on Thursday, June 2. The stock was sold at an average price of $140.63, for a total transaction of $140,630.00. Following the sale, the director now owns 600 shares of the company, valued at $84,378. The transaction was disclosed in a filing with the Securities & Exchange Commission, accessible via this hyperlink. Additionally, COO Eric H. Reynolds sold 585 shares of the company in a trade on Monday, May 9. The stock was sold at an average price of $154.83, for a total transaction of $90,575.55. As a result of the transaction, the chief operating officer now owns 17,289 shares of the company, valued at approximately $2,676,855.87. The disclosure of this sale can be found here. 0.58% of the shares are currently held by company insiders.

CLX stock opened at $140.11 on Friday. The company has a market capitalization of $17.24 billion, a PE ratio of 37.97, a PEG ratio of 4.31 and a beta of 0.18. The company has a debt ratio of 3.28, a quick ratio of 0.40 and a current ratio of 0.71. The company’s 50-day moving average price is $142.50 and its 200-day moving average price is $151.47. The Clorox Company has a one-year low of $120.50 and a one-year high of $191.75.

Clorox (NYSE:CLX – Get Rating) last announced its results on Monday, May 2. The company reported earnings per share (EPS) of $1.31 for the quarter, beating consensus analyst estimates of $0.97 by $0.34. The company posted revenue of $1.81 billion for the quarter, compared to analysts’ estimates of $1.81 billion. Clorox had a return on equity of 92.98% and a net margin of 6.44%. In the same quarter of the previous year, the company had earned earnings per share of $1.62. Equity research analysts expect The Clorox Company to post an EPS of 4.16 for the current fiscal year.

CLX has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft lowered its price target on Clorox shares from $145.00 to $132.00 in a research note on Tuesday. DA Davidson reduced his price target on Clorox shares from $127.00 to $123.00 in a Tuesday, May 3 research note. Barclays lowered its price target on Clorox shares from $126.00 to $115.00 and set an “underweight” rating for the company in a Monday May 23 research note. StockNews.com assumed coverage of Clorox shares in a Thursday, March 31 report. They have placed a “holding” rating on the stock. Finally, Goldman Sachs Group cut its price target on Clorox shares from $145.00 to $127.00 in a Tuesday, March 29 report. Nine research analysts gave the stock a sell rating, five gave the stock a hold rating and one gave the stock a buy rating. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $140.69.

Profile Clorox (Get an assessment)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle and International. The Health and Wellness segment offers cleaning products, such as laundry additives and household cleaning products, primarily under the brands Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex and Formula 409; professional cleaning and disinfecting products under the CloroxPro, Clorox Healthcare and Clorox Total 360 brands; professional catering products under the Hidden Valley brand; and vitamins, minerals and supplements under the RenewLife, Natural Vitality, NeoCell and Rainbow Light brands in the United States.

Read more

Want to see which other hedge funds hold CLX? Visit HoldingsChannel.com for the latest 13F filings and insider trading for The Clorox Company (NYSE:CLX – Get Rating).

Institutional ownership by quarter for Clorox (NYSE:CLX)



Get news and reviews for Clorox Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Clorox and related companies with MarketBeat.com’s FREE daily newsletter.


Source link